Ikarian Capital, LLC Biotechnology

Ikarian Capital, LLC

$606 Million
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
ELYM Eliem Therapeutics, Inc.	$109M	$719,000 0.12% of portfolio	175,088	Q4 2024 Reduced 0.01%
NRIX Nurix Therapeutics, Inc.	$795M	$659,000 0.11% of portfolio	34,985	Q4 2024 Reduced 86.54%
VERU Veru Inc.	$45.7M	$614,000 0.1% of portfolio	945,239	Q4 2024 Reduced 0.12%
ITOS I Teos Therapeutics, Inc.	$264M	$603,000 0.1% of portfolio	78,585	Q4 2024 Added 0.01%
SANA Sana Biotechnology, Inc.	$573M	$594,000 0.1% of portfolio	365,000	Q4 2024 New
OLMA Olema Pharmaceuticals, Inc.	$202M	$536,000 0.09% of portfolio	91,994	Q4 2024 Reduced 0.01%
ABOS Acumen Pharmaceuticals, Inc.	$56.3M	$457,000 0.08% of portfolio	265,769	Q4 2024 Reduced 0.25%
CMMB Chemomab Therapeutics Ltd.	$19.5M	$430,000 0.07% of portfolio	213,052	Q4 2024 Reduced 0.16%
SPRB Spruce Biosciences, Inc.	$9.9M	$410,000 0.07% of portfolio	1,000,000	Q4 2024 New
ELEV Elevation Oncology, Inc.	$14.2M	$400,000 0.07% of portfolio	690,050	Q4 2024 Reduced 0.01%
TVTX Travere Therapeutics, Inc.	$1.41B	$393,000 0.06% of portfolio	22,600	Q4 2024 New
SNSE Sensei Biotherapeutics, Inc.	$14.7M	$324,000 0.05% of portfolio	649,963	Q4 2024 Reduced 0.01%
VYGR Voyager Therapeutics, Inc.	$163M	$316,000 0.05% of portfolio	55,766	Q4 2024 Reduced 0.16%
KPTI Karyopharm Therapeutics Inc.	$47.9M	$278,000 0.05% of portfolio	408,899	Q4 2024 Reduced 0.11%
ANEB Anebulo Pharmaceuticals, Inc.	$32.3M	$264,000 0.04% of portfolio	157,720	Q4 2024 Reduced 0.09%
MGNX Macrogenics Inc	$170M	$260,000 0.04% of portfolio	80,071	Q4 2024 Reduced 0.01%
LRMR Larimar Therapeutics, Inc.	$138M	$223,000 0.04% of portfolio	58,526	Q4 2024 Reduced -0.0%
LYRA Lyra Therapeutics, Inc.	$6.37M	$222,000 0.04% of portfolio	1,058,148	Q4 2024 Added 0.12%
NUVB Nuvation Bio Inc.	$480M	$221,000 0.04% of portfolio	83,407	Q4 2024 Added 0.15%
APLS Apellis Pharmaceuticals, Inc.	$3.02B	$114,000 0.02% of portfolio	3,594	Q4 2024 New
TPST Tempest Therapeutics, Inc.	$8.96M	$88,000 0.01% of portfolio	105,285	Q4 2024 Reduced 0.3%
STOK Stoke Therapeutics, Inc.	$328M	$74,000 0.01% of portfolio	6,798	Q4 2024 Reduced 0.26%
RLMD Relmada Therapeutics, Inc.	$8.58M	$20,000 0.0% of portfolio	40,270	Q4 2024 Reduced 0.25%
IMVT Immunovant, Inc.	$3.55B	$16,000 0.0% of portfolio	600	Q4 2024 New
CADL Candel Therapeutics, Inc.	$336M	$12,000 0.0% of portfolio	1,400	Q4 2024 New
CTMX Cytom X Therapeutics, Inc.	$51.4M	$9,000 0.0% of portfolio	8,924	Q2 2024 New
GLYC Glycomimetics Inc	$15.2M	$1,000 0.0% of portfolio	6,501	Q4 2024 New
FDMT 4 D Molecular Therapeutics, Inc.	$150M	$0 0.0% of portfolio	40	Q4 2024 Added 2.56%
GALT Galectin Therapeutics Inc	$87.4M	$0 0.0% of portfolio	100	Q4 2024 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.